<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022683</url>
  </required_header>
  <id_info>
    <org_study_id>630-0015/A</org_study_id>
    <nct_id>NCT02022683</nct_id>
  </id_info>
  <brief_title>To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV</brief_title>
  <acronym>TRANSFORM</acronym>
  <official_title>A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonx, Inc.</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the clinical outcomes of Endoscopic Lung Volume Reduction using Pulmonx Zephyr
      Endobronchial Valve (EBV) vs. Standard of Care (SoC) in the treatment of heterogeneous
      emphysema patients in a controlled trial design setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Between baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in St George's Respiratory Questionnaire, 6-Min Walk Test, BODE index, mMRC score,</measure>
    <time_frame>Betwenn baseline and 3, 6, 12, 18, and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Target Lobar Volume Reduction (TLVR), Residual Volume, EQ-5D summary index, AEs and SAEs, paO2</measure>
    <time_frame>Change in TLVR between baseline and 45 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>COPD</condition>
  <condition>Heterogeneous Emphysema</condition>
  <arm_group>
    <arm_group_label>Endoscopic Lung Volume Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are implanted Zephyr EBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are given Standard of Care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve</intervention_name>
    <description>Standard Medical Care</description>
    <arm_group_label>Endoscopic Lung Volume Reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heterogeneous emphysema

          -  15% pred &lt; or = FEV1 &lt; or = 45% pred

          -  TLC &gt; 100% and RV &gt; or = 180%

          -  150 m &lt; or = 6MWT &lt; or = 450 m

          -  No collateral ventilation

        Exclusion Criteria:

          -  Contraindication to bronchoscopy

          -  Active pulmonary infection

          -  History of 2 or more exacerbations with hospitalization over the past 12 months

          -  Known pulmonary hypertension

          -  Prior LVR or LVRS procedure

          -  Pregnant or lactating woman

          -  Hypercapnia

          -  Obstruction reversibility (pre vs post-BD FEV1) &gt; 15%

          -  CV in the target lobe or inconclusive Chartis assessment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Hillerdal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Liljensten, DDS, PhD</last_name>
    <phone>0046-723 61 1968</phone>
    <email>eliljensten@liljenstenc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pulmonary Diseases</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoscopic lung volume reduction</keyword>
  <keyword>Endobronchial valves</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
